Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo

Neuropharmacology

Volumn 45, Issue 7, 2003, Pages 945-953

  Moison, Delphine ^a   De Deurwaerdère, Philippe ^a   Cagnotto, Alfredo ^b   Marrazzo, Agostino ^c   Prezzavento, Orazio ^c   Ronsisvalle, Giuseppe ^c   Mennini, Tiziana ^b   Spampinato, Umberto ^a  

^a CNRS   (France)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Dopamine release; DTG; Microdialysis; MR200; Striatum; Receptors

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; HALOTHANE; METHYL 2 [[4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL]METHYL] 1 PHENYLCYCLOPROPANECARBOXYLATE; MR 200; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; DRUG RECEPTOR BINDING; GUINEA PIG; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0142059138     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00253-3     Document Type: Article

References (40)

1. Abercrombie E.D., De Boer P., Heeringa M.J. Biochemistry of somatodendritic dopamine release in substancia nigra: an in vivo comparison with striatal dopamine release. Adv. Pharmacol. 42:1998;133-136.
2. Alonso G., Phan V.L., Guillemain I., Saunier M., Legrand A., Anoal M., Maurice T. Immunocytochemical localization of the sigma 1 receptor in the adult rat central nervous system. Neuroscience. 97:2000;155-170.
3. Bastianetto S., Rouquier L., Perrault G., Sanger D.J. DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways. Neuropharmacology. 34:1995;281-287.
4. Bonhomme N., De Deurwaerdère P., Le Moal M., Spampinato U. Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rat. Neuropharmacology. 34:1995;269-279.
5. Bouchard P., Quirion R. [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience. 76:1997;467-477.
6. Chien C.C., Pasternak G.W. Sigma antagonists potentiate opioid analgesia in rats. Neurosci. Lett. 190:1995;137-139.
7. 3 receptors. J. Neurosci. 18:1998;6528-6538.
8. De Lange E.C., De Boer A.G., Breimer D.D. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv. Drug Deliv. Rev. 45:2000;125-148.
9. Di Chiara G. In vivo brain dialysis of neurotransmitters. Trends Pharmacol. Sci. 11:1990;116-121.
10. Dunnett S.B., Robbins T.W. The functional role of mesotelencephalic dopamine systems. Biol. Rev. Camb. Philos. Soc. 67:1992;491-518.
11. Ela C., Barg J., Vogel Z., Hasin Y., Eilam Y. Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J. Pharmacol. Exp. Ther. 269:1994;1300-1309.
12. 4 receptors in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;22-28.
13. Gonzalez-Alvear G.M., Werling L.L. Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J. Pharmacol. Exp. Ther. 271:1994;212-219.
14. Gonzalez-Alvear G.M., Werling L.L. sigma1 Receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur. J. Pharmacol. 294:1995;713-719.
15. Gudelsky G.A. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur. J. Pharmacol. 286:1995;223-228.
16. Gudelsky G.A. Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat. J. Neural Transm. 106:1999;849-856.
17. Hayashi T., Maurice T., Su T.P. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J. Pharmacol. Exp. Ther. 293:2000;788-798.
18. Hayashi T., Su T.P. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc. Natl. Acad. Sci. USA. 98:2001;491-496.
19. Imperato A., Di Chiara G. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur. J. Pharmacol. 156:1988;385-393.
20. Iyengar S., Dilworth V.M., Mick S.J., Contreras P.C., Monahan J.B., Rao T.S., Wood P.L. Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain: functional interaction with NMDA receptors. Brain Res. 524:1990;322-326.
21. Izenwasser S., Newman A.H., Katz J.L. Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur. J. Pharmacol. 243:1993;201-205.
22. Izenwasser S., Thompson-Montgomery D., Deben S.E., Chowdhury I.N., Werling L.L. Modulation of amphetamine-stimulated (transporter mediated) dopamine release in vitro by sigma2 receptor agonists and antagonists. Eur. J. Pharmacol. 346:1998;189-196.
23. Jaen J.C., Caprathe B.W., Pugsley T.A., Wise L.D., Akunne H. Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J. Med. Chem. 36:1993;3929-3936.
24. King M., Pan Y.X., Mei J., Chang A., Xu J., Pasternak G.W. Enhanced kappa-opioid receptor-mediated analgesia by antisense targeting the sigma1 receptor. Eur. J. Pharmacol. 331:1997;R5-R6.
25. Mennini T., Bernasconi P., Fiori M.G. Neurotoxicity of non-ionic low-osmolar contrast media. A receptor binding study. Invest. Radiol. 28:1993;821-827.
26. Miu P., Karoum F., Toffano G., Commissiong J.W. Regulatory aspects of nigrostriatal dopaminergic neurons. Exp. Brain Res. 91:1992;89-95.
27. Patrick S.L., Walker J.M., Perkel J.M., Lockwood M., Patrick R.L. Increases in rat striatal extracellular dopamine and vacuous chewing produced by two sigma receptor ligands. Eur. J. Pharmacol. 231:1993;243-249.
28. Paxinos G., Watson C. The Rat Brain: In Stereotaxic Coordinates. 4:1998;Academic Press, NY.
29. Pehek E.A., Yamamoto B.K. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63:1994;2118-2124.
30. Pozzi L., Trabace L., Invernizzi R., Samanin R. Intranigral, GR 113808, a selective 5-HT4 receptor antagonist, attenuates morphine-stimulated dopamine release in the rat striatum. Brain Res. 692:1995;265-268.
31. Ronsisvalle G., Marrazzo A., Prezzavento O., Cagnotto A., Mennini T., Parenti C., Scoto G.M. Opioid and sigma receptor studies. New developments in the design of selective sigma ligands. Pure Appl. Chem. 73:2001;1499-1509.
32. Schaus J.M., Bymaster F.P. Dopaminergic approaches to anthipsychotic agents. Ann. Rep. Med. Chem. 33:1998;1-10.
33. Skuza G., Golembiowska K., Wedzony K. Effect of EMD 57445, the selective sigma receptor ligand, on the turnover and release of dopamine. Pol. J. Pharmacol. 50:1998;61-64.
34. Steinfels G.F., Tam S.W. Selective sigma receptor agonist and antagonist affect dopamine neuronal activity. Eur. J. Pharmacol. 163:1989;167-170.
35. Takahashi S., Horikomi K., Kato T. MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. Eur. J. Pharmacol. 427:2001;211-219.
36. Vargas H.M., Pechnick R.N. Binding affinity and antimuscarinic activity of sigma and phencyclidine receptor ligands. Eur. J. Pharmacol. 195:1991;151-156.
37. Vilner B.J., Bowen W.D. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J. Pharmacol. Exp. Ther. 292:2000;900-911.
38. Walker J.M., Bowen W.D., Patrick S.L., Williams W.E., Mascarella S.W., Bai X., Carroll F.I. A comparison of (-)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of sigma 2 receptors in motor function. Eur. J. Pharmacol. 231:1993;61-68.
39. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., Rice K.C. Sigma receptors: biology and function. Pharmacol. Rev. 42:1990;355-402.
40. 3H] dopamine release from mesolimbique and mesocortical areas of guinea brain by sigma receptor. Schizophrenia Res. 21:1996;51-62.